Drugs.com - Monthly Update December 2025
This month, discover the Wegovy tablet, the first oral GLP-1 weight loss medication to be approved, Myqorzo's long-awaited treatment for obstructive hypertrophic cardiomyopathy, and several other exciting new FDA approvals. Explore these key stories and more in our December 2025 round-up.
- Wegovy (semaglutide) tablet, the first oral GLP-1 for weight loss, with significant efficacy in patient trials.
- Myqorzo (aficamten), a long-awaited and major addition to obstructive hypertrophic cardiomyopathy treatment that improves exercise capacity.
- Exdensur (depemokimab-ulaa), a new long-term, add-on treatment for severe eosinophilic asthma with twice-yearly injections.
- Jaypirca (pirtobrutinib), a non-covalent BTK inhibitor whose approval has been extended to include chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Lerochol (lerodalcibep-liga), a third-generation, PCSK9 inhibitor for high cholesterol self-administered via a monthly injection.
- Breyanzi (lisocabtagene maraleucel), a CAR T cell therapy with extended approval to include relapsed or refractory marginal zone lymphoma.
Chapters
- (00:00) - Intro
- (00:22) - Overview
- (00:34) - Wegovy
- (01:16) - Myqorzo
- (02:07) - Exdensur
- (02:56) - Jaypirca
- (03:31) - Lerochol
- (04:09) - Breyanzi
- (04:46) - Outro
Follow Drugs.com:
- X, Facebook, Youtube
- Signup to our newsletters
- Download the app
